<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>前免疫</title><link/>https://pubmed.ncbi.nlm.nih.gov/?sort=date&amp;term=101560960%20%20%20%5BNLMID%5D&amp;fc = none&amp;v=2.18.0.post9+E46 2414＆utm_content = 101560960＆ff = 20250408082135＆utm_source = chrome＆utm_medium = rss＆utm_campaign =期刊<description>前免疫：PubMed的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/?sort=date&amp;term=101560960%20%5BNLMID%5D&amp;fc=None&amp;v=2.18.0.post9+e462414&amp;utm_content=101560960&amp;ff=20250408082135&amp;utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS提要（2.18.0.post9+E462414）</generator><language> en</language><lastbuilddate>星期二，2025年4月8日12:21:36 +0000</lastbuilddate><pubDate> Tue, 08 Apr 2025 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title>甲基转移酶样3介导的RNA N &lt;SUP>; 6 &lt;/sup>;  - 甲基腺苷有助于免疫失调：诊断生物标志物和治疗靶标</title><link/>https://pubmed.ncbi.nlm.nih.gov/40196133/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250408082135＆v = 2.18.0.post9+e462414<description>甲基转移酶样3（METTL3）在转录后基因调节中起着至关重要的作用。大量证据将METTL3与各种免疫功能障碍联系起来，例如在病毒感染过程中抑制抗病毒药物以及在自身免疫性疾病，髓样白血病，皮肤癌和抗癌免疫疗法等条件下的免疫耐受性破坏。但是，目前缺少对该证据的详尽审查和分析，这限制了对Mettl3的理解。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月24日； 16：1523503。 doi：10.3389/fimmu.2025.1523503。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">甲基转移酶样3（METTL3）在转录后基因调节中起着至关重要的作用。大量证据将METTL3与各种免疫功能障碍联系起来，例如在病毒感染过程中抑制抗病毒药物以及在自身免疫性疾病，髓样白血病，皮肤癌和抗癌免疫疗法等条件下的免疫耐受性破坏。但是，目前缺少对该证据的彻底审查和分析，这限制了对METTL3机制的理解和免疫功能障碍的重要性。这篇综述旨在阐明METTL3在这些免疫问题中的作用和机制，强调其联系并提出对其免疫反应调节的新见解。分析在这项综述中结果表明，METTL3会阻碍抗病毒免疫，恶化病毒复制和感染，并破坏免疫耐受性。相反，调节METTL3可增强抗病毒免疫力并促进病毒清除率。此外，临床数据证实了这些发现，表明METTL3过表达与对病毒感染和自身免疫性条件的敏感性增加有关。这篇综述为将METTL3视为一种新型调节剂，重要的诊断生物标志物以及治疗免疫功能障碍的潜在靶标建立了理论基础。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40196133/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250408082135&v=2.18.0.post9+e462414">40196133</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11973086/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250408082135&v=2.18.0.post9+e462414">PMC11973086</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1523503>10.3389/fimmu.2025.1523503</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40196133</guid><pubDate> Tue, 08 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Deshuang Zhang</dc:creator><dc:creator> Ting Xu</dc:creator><dc:creator>小氧气高</dc:creator><dc:creator>yi qu</dc:creator><dc:creator>小朱恩su</dc:creator><dc:date> 2025-04-08</dc:date><dc:source>免疫学领域</dc:source><dc:title>甲基转移酶样3介导的RNA N &lt;SUP>; 6 &lt;/sup>;  - 甲基腺苷有助于免疫失调：诊断生物标志物和治疗靶标</dc:title><dc:identifier>PMID：40196133</dc:identifier><dc:identifier> PMC：PMC11973086</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1523503</dc:identifier></item><item><title>携带&lt;em>; nod2 &lt;/em>;变体的自发性疾病的小儿患者队列中的基因型 - 表型相关性</title><link/>https://pubmed.ncbi.nlm.nih.gov/40196132/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250408082135＆v = 2.18.0.post9+e462414<description>结论：这是第一个评估全身自身炎性疾病和NOD2变体儿童基因型/表型特征的研究。尽管初步和受样本量的影响，但结果不允许对NOD2突变引起的单基因疾病的明确结论，但显然是BLAU综合征。 NOD结构域中的变体似乎与更均匀的临床表型有关。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月24日； 16：1439333。 doi：10.3389/fimmu.2025.1439333。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：自发性疾病（AIDS）是一组疾病，其特征是先天免疫系统过度激活，并具有自发炎症发作，会影响不同的器官。文献中描述了许多单一或获得的自身炎症性疾病。最近，已经引入了具有多基因或复杂遗传的疾病概念。含有2（NOD2）基因变异的核苷酸结合寡聚结构域与克罗恩病（CD），BLAU综合征和最近的多基因自炎性疾病有关，其发作称为NOD2相关的自身炎性疾病（NAID）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：我们研究的目的是描述携带<i>NOD2</i>变体的自发性疾病患者的小儿同类，并评估基因型 - 表型相关性。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：二十五名自自炎性疾病和<i>NOD2</i>变体的儿童参与了研究。根据所涉及的蛋白质结构域将患者分为3组。分析了人口统计学和临床​​特征，成像，实验室检查和治疗。将我们患者的特征与YAO在2016  -  2018年描述的成年队列的特征进行了比较。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：发烧是我们儿童的主要临床特征（68％），长发作和不规则的复发模式。该疾病通常影响皮肤（40％），关节（72％），肠（60％）和淋巴系统（52％）。血清炎和感觉性耳聋的频率较低。在大多数患者中，不包括非甾体类抗炎药（NSAID），经常使用糖皮质激素具有令人满意的临床反应。在疾病控制差的患者或糖皮质激素细胞后的新叶子中，使用非生物和生物药物的反应可变。这两个最有代表性的组之间的比较表明，位于NOD结构域上的变异的患者表现出更均匀的临床特征，并参与了某些目标器官。将我们的患者与文献中描述的成人队列进行了比较，但差异很小。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：这是第一个评估全身自身炎性疾病和<i>NOD2</i>变体儿童基因型/表型特征的研究。尽管初步和受样本量的影响，但结果不允许对<i>NOD2</i>突变引起的单基因疾病的明确结论，但显然是BLAU综合征。 NOD结构域中的变体似乎与更均匀的临床表型有关。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40196132/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250408082135&v=2.18.0.post9+e462414">40196132</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11973280/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250408082135&v=2.18.0.post9+e462414">PMC11973280</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1439333>10.3389/fimmu.2025.1439333</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40196132</guid><pubDate> Tue, 08 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Marco Francesco Natale</dc:creator><dc:creator>卡米拉·塞拉尼（Camilla Celani）</dc:creator><dc:creator>西尔维亚·费德里克（Silvia Federici）</dc:creator><dc:creator> Chiara Passarelli</dc:creator><dc:creator> Chiara Perrone</dc:creator><dc:creator> Emiliano Marasco</dc:creator><dc:creator> Fabrizio de Benedetti</dc:creator><dc:creator> Antonella Insalaco</dc:creator><dc:date> 2025-04-08</dc:date><dc:source>免疫学领域</dc:source><dc:title>携带&lt;em>; nod2 &lt;/em>;变体的自发性疾病的小儿患者队列中的基因型 - 表型相关性</dc:title><dc:identifier>PMID：40196132</dc:identifier><dc:identifier> PMC：PMC11973280</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1439333</dc:identifier></item><item><title>发现KDM5D是通过生物信息学分析确定的创伤性脑损伤的新生物标志物</title><link/>https://pubmed.ncbi.nlm.nih.gov/40196131/?utm_source = chrome&amp;utm_medium = rsss＆utm_camp aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250408082135＆v = 2.18.0.post9+e462414<description>结论：根据生物信息学分析和动物实验的结果，KDM5D是TBI诊断和预后的潜在生物标志物。此外，对KDM5D的研究可能会发展为新的血清标记物，为进一步的临床液体活检提供了新的指标，并在一定程度上有助于预防TBI和肿瘤。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月24日； 16：1538561。 doi：10.3389/fimmu.2025.1538561。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：创伤性脑损伤（TBI）由于治疗差和预后而对全球经济造成了重大负担。当前的TBI标记不能全面反映疾病状况。因此，确定更有意义的生物标志物对改善TBI患者的预后和临床治疗是有益的。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：从基因表达综合（GEO）数据库获得TBI的基因表达谱。对差异表达的基因（DEG）进行了富集分析，并通过蛋白质 - 蛋白质相互作用网络和细胞调节模块鉴定了关键的潜在基因。 ROC曲线用于构建轮毂基因的诊断模型。进行了免疫荧光实验，以检测TBI大鼠模型中候选生物标志物的表达。最后，我们研究了正常的人体器官和泛肿瘤组织中TBI生物标志物的表达，并评估了它们与不同肿瘤中免疫浸润的相关性。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在TBI患者的四个大脑区域中，总共确定了44摄氏度。富集分析表明，这些基因主要参与细胞内和细胞信号转导途径。此外，通过不同的模块分析确定了三个枢纽基因RPS4Y1，KDM5D和NLGN4Y。 ROC曲线诊断模型还证实了这些基因在血清中的诊断值也很高。随后，通过免疫荧光实验在TBI大鼠的脑组织中检测到KDM5D的存在。与正常大鼠相比，TBI大鼠皮质区域的KDM5D表达增加，海马区域没有显着变化，与TBI患者的观察结果一致。免疫浸润分析表明，髋关节和PCX中免疫细胞亚群的变化表明，血浆细胞和CD8 T细胞在TBI（髋关节）中降低表达，而中性粒细胞在TBI（PCX）中表达不足。 Pan-Canter分析表明，KDM5D在23种癌症中显着上调，在3种癌症中下调，并与10种癌症中的免疫浸润显着相关。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：根据生物信息学分析和动物实验的结果，KDM5D是TBI诊断和预后的潜在生物标志物。此外，对KDM5D的研究可能会发展为新的血清标记物，为进一步的临床液体活检提供了新的指标，并在一定程度上有助于预防TBI和肿瘤。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40196131/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250408082135&v=2.18.0.post9+e462414">40196131</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11973351/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250408082135&v=2.18.0.post9+e462414">PMC11973351</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1538561>10.3389/fimmu.2025.1538561</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40196131</guid><pubDate> Tue, 08 Apr 2025 06:00:00 -0400</pubDate><dc:creator>邓凡丁</dc:creator><dc:creator>蒙格杨</dc:creator><dc:creator>Xinou Zheng</dc:creator><dc:creator>明赵</dc:creator><dc:date>2025-04-08</dc:date><dc:source>免疫学领域</dc:source><dc:title>发现KDM5D是通过生物信息学分析确定的创伤性脑损伤的新生物标志物</dc:title><dc:identifier>PMID：40196131</dc:identifier><dc:identifier> PMC：PMC11973351</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1538561</dc:identifier></item><item><title>建立基于炎症性细胞因子的预测模型，用于延长术后术后长时间肠胃切除术：一项前瞻性队列研究</title><link/>https://pubmed.ncbi.nlm.nih.gov/40196130/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250408082135＆v = 2.18.0.post9+e462414<description>结论：我们为胃癌开发了一种新颖且易于使用的预测，该预测主要基于炎症介质的术后水平。该模型进一步阐明了炎症因子与PPOI的发生之间的确切关系，并帮助我们从临床上确定PPOI的高风险基团，以进行早期干预。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月24日； 16：1552944。 doi：10.3389/fimmu.2025.1552944。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：术后长时间的回肠（PPOI）是术后常见的腹部并发症，与炎症反应密切相关。但是，缺乏预测胃癌患者PPOI的有效方法。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：222例患者在我们中心进行了自由基胃切除术，并分为训练组和验证队列。进行了接收器操作特征（ROC）曲线分析以及单变量和多变量逻辑回归模型，以帮助滤波变量包含在预测模型中。然后建立了PPOI的nom图。计算ROC曲线（AUC）下的面积以评估预测准确性。使用诊断校准曲线来评估列诺图的合适性。采用决策曲线分析（DCA）来评估其临床实用性。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：手术后的PPOI患者发现，在术后第一个日，IL-6，IL-10，TNF-α和CRP的显着增加。单变量和多元分析表明，年龄≥65，IL-6和IL-10是PPOI的独立预测因素。随后，我们开发了PPOI的预测列图，其中包括年龄IL-6，IL-10和TNF-α。培训和验证小组的进一步验证证明了我们模型的良好预测功效以及有利的临床益处。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：我们为胃癌开发了一种新颖且易于使用的预测，该预测主要基于炎症介质的术后水平。该模型进一步阐明了炎症因子与PPOI的发生之间的确切关系，并帮助我们从临床上确定PPOI的高风险基团，以进行早期干预。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40196130/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250408082135&v=2.18.0.post9+e462414">40196130</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11973057/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250408082135&v=2.18.0.post9+e462414">PMC11973057</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1552944>10.3389/fimmu.2025.1552944</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40196130</guid><pubDate> Tue, 08 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Chao Sui</dc:creator><dc:creator> Beibei Wang</dc:creator><dc:creator> Zhao</dc:creator><dc:creator> Yuntian Guo</dc:creator><dc:creator> Jinxin Zhu</dc:creator><dc:creator>冯y</dc:creator><dc:creator>小周</dc:creator><dc:creator>Xuefeng Bu</dc:creator><dc:creator>张张</dc:creator><dc:date>2025-04-08</dc:date><dc:source>免疫学领域</dc:source><dc:title>建立基于炎症性细胞因子的预测模型，用于延长术后术后长时间肠胃切除术：一项前瞻性队列研究</dc:title><dc:identifier>PMID：40196130</dc:identifier><dc:identifier> PMC：PMC11973057</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1552944</dc:identifier></item><item><title>结核肉芽肿的微环境：治疗的进步和机会</title><link/>https://pubmed.ncbi.nlm.nih.gov/40196129/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250408082135＆v = 2.18.0.post9+e462414<description>结核病（TB）的标志性组织病变是肉芽肿。这些多细胞结构表现出不同程度的细胞复杂性，是动态的，并且在宿主之间和宿主之间显示出相当大的多样性。基于总体病理特征，尤其是静脉曲张和坏死的分类，历史上是在将分枝杆菌鉴定为TB的病因之前创造的。最近，基于免疫细胞组成，代谢物丰度和...的肉芽肿分区化</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月24日； 16：1575133。 doi：10.3389/fimmu.2025.1575133。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结核病（TB）的标志性组织病变是肉芽肿。这些多细胞结构表现出不同程度的细胞复杂性，是动态的，并且在宿主之间和宿主之间显示出相当大的多样性。基于总体病理特征，尤其是静脉曲张和坏死的分类，历史上是在将分枝杆菌鉴定为TB的病因之前创造的。最近，基于免疫细胞组成，代谢物丰度和身体特征的肉芽肿分区引起了人们的注意。随着单细胞分析的出现，已经确定了结核病颗粒中不同的微环境和细胞生态系统。我们总结了结核病肉芽肿的结构，并突出了它们的细胞异质性，包括细胞壁nir以及物理因素，例如调节病变命运的氧梯度。我们讨论了治疗的机会，突出了新的模型以及在拆卸颗粒瘤特征和轨迹方面的<i>硅胶</i>建模的力量。了解肉芽肿微环境与疾病病理生理学的相关性将有助于开发更有效的干预措施，例如针对结核病的宿主定向疗法。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40196129/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250408082135&v=2.18.0.post9+e462414">40196129</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11973276/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250408082135&v=2.18.0.post9+e462414">PMC11973276</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1575133>10.3389/fimmu.2025.1575133</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40196129</guid><pubDate> Tue, 08 Apr 2025 06:00:00 -0400</pubDate><dc:creator>格萨·克鲁格（Gesa Krueger）</dc:creator><dc:creator>沙阿·菲萨尔（Shah Faisal）</dc:creator><dc:creator> anca dorhoi</dc:creator><dc:date> 2025-04-08</dc:date><dc:source>免疫学领域</dc:source><dc:title>结核肉芽肿的微环境：治疗的进步和机会</dc:title><dc:identifier>PMID：40196129</dc:identifier><dc:identifier> PMC：PMC11973276</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1575133</dc:identifier></item><item><title>肿瘤微环境内的潜在目标-MT1 -MMP</title><link/> https://pubmed.ncbi.nlm.nih.gov/40196128/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250408082135＆v = 2.18.0.post9+e462414<description>基质金属蛋白酶是修饰肿瘤微环境的组成部分，并通过降解细胞外基质，释放细胞因子并影响免疫细胞的募集来促进肿瘤进展。在基质金属蛋白酶中，膜型基质金属蛋白酶1（MT1-MMP/MMP14）是第一个鉴定出的膜型MMP，它是一种必不可少的蛋白水解酶，可实现肿瘤浸润和转移性进展。考虑到...的关键作用</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月24日； 16：1517519。 doi：10.3389/fimmu.2025.1517519。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">基质金属蛋白酶是修饰肿瘤微环境的组成部分，并通过降解细胞外基质，释放细胞因子并影响免疫细胞的募集来促进肿瘤进展。在基质金属蛋白酶中，膜型基质金属蛋白酶1（MT1-MMP/MMP14）是第一个鉴定出的膜型MMP，它是一种必不可少的蛋白水解酶，可实现肿瘤浸润和转移性进展。鉴于MT1-MMP在肿瘤进展中的关键作用以及其在肿瘤中的过表达与多种癌症类型的不利预后之间的相关性，因此对MT1-MMP的潜在功能机制的全面理解至关重要。这些知识将有助于旨在针对MT1-MMP的各种抗肿瘤疗法的发展。尽管当代研究强调了MT1-MMP在靶向癌症治疗中的巨大潜力，但与其在细胞疗法中的应用有关的研究仍然相对有限。在这篇综述中，我们描述了MT1-MMP表达的结构特征和调节机制，以及其在肿瘤发生中的生物学意义。最后，我们讨论了针对MT1-MMP的抗肿瘤疗法的当前状态和前景。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40196128/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250408082135&v=2.18.0.post9+e462414">40196128</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11973285/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250408082135&v=2.18.0.post9+e462414">PMC11973285</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1517519>10.3389/fimmu.2025.1517519</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40196128</guid><pubDate> Tue, 08 Apr 2025 06:00:00 -0400</pubDate><dc:creator>金隆刘</dc:creator><dc:creator>Yijing Li</dc:creator><dc:creator> Xueqi Lian</dc:creator><dc:creator> Chenglin Zhang</dc:creator><dc:creator>简峰</dc:creator><dc:creator>Hongfei Tao</dc:creator><dc:creator>王王</dc:creator><dc:date>2025-04-08</dc:date><dc:source>免疫学领域</dc:source><dc:title>肿瘤微环境内的潜在目标-MT1 -MMP</dc:title><dc:identifier> PMID：40196128</dc:identifier><dc:identifier> PMC：PMC11973285</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1517519</dc:identifier></item><item><title> CMTM3通过影响肺血管内皮通透性和ARDS炎症来调节血管内皮细胞功能障碍</title><link/>https://pubmed.ncbi.nlm.nih.gov/40196127/?utm_source = chrome&amp;utm_medium = rsss＆utm_camp aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250408082135＆v = 2.18.0.post9+e462414<description>简介：CMTM3是人类趋化因子样因子超家族的成员。 CMTM3在急性呼吸窘迫综合征（ARDS）中的机械作用尚不清楚。这项研究研究了CMTM3在ARDS进展中的作用及其对血管内皮细胞功能的影响。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月24日； 16：1544610。 doi：10.3389/fimmu.2025.1544610。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">简介：CMTM3是人类趋化因子样因子超家族的成员。 CMTM3在急性呼吸窘迫综合征（ARDS）中的机械作用尚不清楚。这项研究研究了CMTM3在ARDS进展中的作用及其对血管内皮细胞功能的影响。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：通过用脂多糖（LPS）或低氧/reoxygenation处理人类脐带血管内皮细胞（HUVEC）中的ARDS建模。我们评估了LPS和低氧/重氧刺激的HUVEC细胞中的CMTM3表达水平。此外，我们评估了使用具有CMTM3过表达（ADCMTM3）或敲除（SHCMTM3）的HUVEC细胞，在ARDS条件下，在ARDS条件下，CMTM3在血管内皮细胞的渗透率和炎症反应中的作用（SHCMTM3）。同时，我们产生了CMTM3敲除（CMTM3KO）小鼠，并评估了肺血管通透性，炎症性肺损伤以及CMTM3KO-pard和WT-pard ads模型小鼠之间的差异。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：与对照组相比，用LPS刺激的HUVEC和缺氧/re氧的CMTM3表达明显更高（P &lt;0.05）。与ADSHAM-HUVEC相比，LPS刺激的ADCMTM3-HUVEC和缺氧/重氧刺激的细胞渗透性明显更高（P &lt;0.05）以及IL-6和TNF-α表达水平（P &lt;0.05）。相反，用LPS刺激的SHCMTM3-HUVEC和缺氧/氧化刺激显示出明显降低的细胞渗透性，以及IL-6和TNF-α表达水平（P &lt;0.05）。体内ARDS建模实验表明，与野生型小鼠相比，CMTM3敲除ARDS小鼠的生存率显着更高（P = 0.0194），并且显着降低了肺损伤和肺血管通透性（P &lt;0.05）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">讨论：这些发现表明，CMTM3通过影响肺血管内皮细胞和肺部炎症的渗透性而在ARDS的发展中起关键作用。因此，CMTM3是ARDS中潜在的治疗靶标。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40196127/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250408082135&v=2.18.0.post9+e462414">40196127</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11973065/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250408082135&v=2.18.0.post9+e462414">PMC11973065</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1544610>10.3389/fimmu.2025.1544610</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40196127</guid><pubDate> Tue, 08 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Ziyan Xiao</dc:creator><dc:creator>帮派周</dc:creator><dc:creator>Haiyan Xue</dc:creator><dc:creator> Lihe Chen</dc:creator><dc:creator> Xiujuan Zhao</dc:creator><dc:creator> Shu Li</dc:creator><dc:creator> Chun Fu</dc:creator><dc:creator>郑州王</dc:creator><dc:creator>冯豪</dc:creator><dc:date>2025-04-08</dc:date><dc:source>免疫学领域</dc:source><dc:title>CMTM3通过影响肺血管内皮通透性和ARDS炎症来调节血管内皮细胞功能障碍</dc:title><dc:identifier>PMID：40196127</dc:identifier><dc:identifier> PMC：PMC11973065</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1544610</dc:identifier></item><item><title>记忆B细胞增殖驱动Chadox1和BNT162B2 SARS-COV-2疫苗之间中和反应的差异</title><link/>https://pubmed.ncbi.nlm.nih.gov/40196126/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250408082135＆v = 2.18.0.post9+e462414<description>简介：针对Covid-19的疫苗接种在减轻全球疾病负担方面是关键的。但是，III期试验结果和观察性研究强调了疫苗技术和给药方案的疗效差异。值得注意的是，与腺病毒（ADV）疫苗相比，mRNA疫苗表现出较高的有效性，尤其是延长的给药间隔。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月24日； 16：1487066。 doi：10.3389/fimmu.2025.1487066。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">简介：针对Covid-19的疫苗接种在减轻全球疾病负担方面是关键的。但是，III期试验结果和观察性研究强调了疫苗技术和给药方案的疗效差异。值得注意的是，与腺病毒（ADV）疫苗相比，mRNA疫苗表现出较高的有效性，尤其是延长的给药间隔。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：使用托内机械建模，本研究阐明了这些变化，并揭开了在细胞水平上塑造免疫反应的生物学机制。我们使用了有关澳大利亚医护人员的第二剂剂量疫苗后第二剂剂量后，我们使用了记忆B细胞，浆液和抗体滴度变化的数据。除了这个数据集外，我们构建了一个动力学模型的体液免疫模型，该模型共同捕获了多个免疫标记的动力学，并将分层效应整合到该动力学模型中，包括年龄，给药时间表和疫苗类型。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：我们的分析估计，在调整年龄，剂量和启动剂量之间的间隔后，mRNA疫苗比ADV疫苗诱导的记忆B细胞增殖高2.1倍。另外，将第二次疫苗剂量和启动剂量之间的持续时间延长了28天，使每个浆液浓度的中和抗体产生增加了30％。我们还发现，当对ADV疫苗和更长的给药方案中使用mRNA疫苗时，第二剂量后的抗体反应更加持久。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">讨论：对疫苗接种响应疫苗接种的主宿内动力学可以帮助优化疫苗给药方案，提高不同人群群体的疫苗功效，并为未来疫苗的设计提供了增强对新兴病原体的保护。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40196126/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250408082135&v=2.18.0.post9+e462414">40196126</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11974255/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250408082135&v=2.18.0.post9+e462414">PMC11974255</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1487066>10.3389/fimmu.2025.1487066</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40196126</guid><pubDate> Tue, 08 Apr 2025 06:00:00 -0400</pubDate><dc:creator>大卫·霍奇森（David Hodgson）</dc:creator><dc:creator>是刘</dc:creator><dc:creator>路易丝·卡罗兰（Louise Carolan）</dc:creator><dc:creator> Siddhartha Mahanty</dc:creator><dc:creator> Kanta Subbarao</dc:creator><dc:creator> Sheena G Sullivan</dc:creator><dc:creator>安妮特·福克斯</dc:creator><dc:creator>亚当·库查斯基（Adam Kucharski）</dc:creator><dc:date> 2025-04-08</dc:date><dc:source>免疫学领域</dc:source><dc:title>记忆B细胞增殖驱动Chadox1和BNT162B2 SARS-COV-2疫苗之间中和反应的差异</dc:title><dc:identifier>PMID：40196126</dc:identifier><dc:identifier> PMC：PMC11974255</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1487066</dc:identifier></item><item><title>全面的多组分分析将pycard识别为骨关节炎滑膜巨噬细胞中与凋亡相关的关键基因</title><link/>https://pubmed.ncbi.nlm.nih.gov/40196125/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250408082135＆v = 2.18.0.post9+e462414<description>结论：Pycard被确定为OA巨噬细胞中的核心凋亡基因，并确定了57种潜在的治疗化合物。这项研究为OA的潜在治疗目标提供了宝贵的见解。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月24日； 16：1558139。 doi：10.3389/fimmu.2025.1558139。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：骨关节炎（OA）是一种严重损害生活质量的慢性关节疾病。滑膜炎在OA进展中起关键作用，而凋亡是一种与先天免疫炎症相关的程序性细胞死亡形式，可能有助于OA滑膜炎的发病机理。然而，凋亡在OA发病机理中的确切作用仍然很少理解。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们对散装RNA测序数据进行了分析，以检查OA滑膜中与凋亡相关基因的表达谱。采用了套索-Cox回归模型来鉴定关键基因。单细胞RNA测序数据用于验证这些基因在特定的滑细胞簇中的表达。在具有较高或低表达核心基因的巨噬细胞中差异表达的基因（DEG）进行富集分析。构建了蛋白质 - 蛋白质相互作用（PPI）网络以鉴定枢纽基因，并预测了潜在的治疗化合物。进行共识聚类分析以检查中心基因与疾病状态之间的相关性。在将Pycard识别为OA巨噬细胞中的核心凋亡基因之后，我们评估了OA滑膜中的Pycard的表达水平，并验证了Pycard及其相关核心基因在M1巨噬细胞中的表达。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：总共确定了二十个与凋亡相关的DEG，并通过套索回归选择了六个核心基因。 pycard被确定为巨噬细胞中的关键凋亡基因。此外，预测了57种针对这些基因的治疗化合物。验证证实了Pycard在OA滑膜和M1巨噬细胞中的上调。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：Pycard被确定为OA巨噬细胞中的核心凋亡基因，并确定了57种潜在的治疗化合物。这项研究为OA的潜在治疗目标提供了宝贵的见解。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40196125/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250408082135&v=2.18.0.post9+e462414">40196125</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11973068/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250408082135&v=2.18.0.post9+e462414">PMC11973068</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1558139>10.3389/fimmu.2025.1558139</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40196125</guid><pubDate> Tue, 08 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Zihao Yao</dc:creator><dc:creator> yuexin li</dc:creator><dc:creator>汉文迈</dc:creator><dc:creator>Zhuolun Wang</dc:creator><dc:creator> Haiyan Zhang</dc:creator><dc:creator> Daozhang Cai</dc:creator><dc:creator>江民王</dc:creator><dc:date>2025-04-08</dc:date><dc:source>免疫学领域</dc:source><dc:title>全面的多组分分析将pycard识别为骨关节炎滑膜巨噬细胞中与凋亡相关的关键基因</dc:title><dc:identifier>PMID：40196125</dc:identifier><dc:identifier> PMC：PMC11973068</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1558139</dc:identifier></item><item><title> T细胞的动态功能评估揭示了多发性患者的早期抑制与不良结果相关</title><link/>https://pubmed.ncbi.nlm.nih.gov/40196124/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250408082135＆v = 2.18.0.post9+e462414<description>简介：大多数创伤患者都需要重症监护治疗，并且容易患上持续的炎症和免疫抑制，这可能导致多器官功能障碍综合征（MOD）和对长期护理设施的依赖。 T细胞在创伤后发生数量和功能变化。使用功能性免疫监测来预测单个临床结果，对多重型患者的T细胞功能障碍进行表征。此外，逆转T细胞的潜力... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月24日； 16：1538516。 doi：10.3389/fimmu.2025.1538516。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">简介：大多数创伤患者都需要重症监护治疗，并且容易患上持续的炎症和免疫抑制，这可能导致多器官功能障碍综合征（MOD）和对长期护理设施的依赖。 T细胞在创伤后发生数量和功能变化。使用功能性免疫监测来预测单个临床结果，对多重型患者的T细胞功能障碍进行表征。此外，检查了使用白介素（IL）-7逆转T细胞功能障碍的潜力。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：从健康个体和入院后的多发性多发性疾病患者（损伤严重程度得分≥18）中抽取血液样本，8、24和48小时5和10天。通过酶连接的免疫点（ELISPOT）评估了全血中T细胞的CD3/28刺激的细胞因子产生。通过计数和流式细胞仪定量T细胞子集。不利的身体表现结果被定义为需要长期护理的死亡或新功能残疾。次要结果是MOD和院内死亡率的发展。将IL-7离体添加以测试细胞因子紊乱的可逆性。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：34例患者被招募。不同的结果组显示损伤严重程度没有差异。身体表现良好的患者显示，功能性T细胞特异性干扰素γ（IFN-γ）和IL-17（8小时）和较低的IL-10产生（第5天）和CD8 T细胞浓度较高。没有MODS发育的患者显示出较高的IFN-γ（第10天），IL-2（8小时）和IL-17产生较高（入院，第5天）。关于院内死亡率没有差异。全身性血液IFN-γ，IL-2和IL-10浓度仅与mod相关（24小时）。全身CD8 T细胞数与功能性IFN-γ的产生相关。用IL-7全血刺激增加了功能性T细胞IFN-γ释放。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">讨论：我们的研究揭示了促炎（IFN-γ，IL-2，IL-17）和免疫抑制（IL-10）亚型的早期特征T细胞功能障碍。我们的数据表明，T细胞释放细胞因子的功能能力，但不能使用全身细胞因子浓度来预测创伤后的结果。我们假设促促和抗炎T细胞的早期刺激使多重型患者受益。 IL-7给药可以实现功能性IFN-γ释放的增强。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40196124/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250408082135&v=2.18.0.post9+e462414">40196124</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11973370/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250408082135&v=2.18.0.post9+e462414">PMC11973370</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1538516>10.3389/fimmu.2025.1538516</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40196124</guid><pubDate> Tue, 08 Apr 2025 06:00:00 -0400</pubDate><dc:creator>托比亚斯·乔斯（Tobias Jooss）</dc:creator><dc:creator> Katharina Maier</dc:creator><dc:creator>莉娜·玛丽·里查德（Lena-Marie Reichardt）</dc:creator><dc:creator> Bianca Hindelang</dc:creator><dc:creator> lönnaSüberkrüb</dc:creator><dc:creator>金·莉娜·汉伯格（Kim Lena Hamberger）</dc:creator><dc:creator>茉莉·玛丽亚·布洛（JasminMariaBülow）</dc:creator><dc:creator> Konrad Schuetze</dc:creator><dc:creator> Florian Gebhard</dc:creator><dc:creator>马可曼恩斯</dc:creator><dc:creator>丽贝卡·霍尔布鲍尔（Rebecca Halbgebauer）</dc:creator><dc:creator>丽莎·沃尔基特（Lisa Wohlgemuth）</dc:creator><dc:creator>马库斯·胡伯·朗（Markus Huber-Lang）</dc:creator><dc:creator>伯纳·雷亚</dc:creator><dc:creator>克里斯蒂安·B·伯格曼（Christian B Bergmann）</dc:creator><dc:date> 2025-04-08</dc:date><dc:source>免疫学领域</dc:source><dc:title>T细胞的动态功能评估揭示了多发性患者的早期抑制与不良结果相关</dc:title><dc:identifier>PMID：40196124</dc:identifier><dc:identifier> PMC：PMC11973370</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1538516</dc:identifier></item><item><title>巨噬细胞极化与代谢的交点处的线粒体动力学</title><link/>https://pubmed.ncbi.nlm.nih.gov/40196123/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250408082135＆v = 2.18.0.post9+e462414<description>巨噬细胞是先天免疫中至关重要的哨兵，如果没有内部代谢重编程，则无法执行其功能。线粒体动力学，尤其是线粒体融合和裂变，有助于维持线粒体稳态。过去的线粒体动力学与巨噬细胞之间的联系集中在巨噬细胞的免疫功能上。我们对线粒体动力学与巨噬细胞代谢之间进行了创新的总结并提出了联系。他们之中，... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月24日； 16：1520814。 doi: 10.3389/fimmu.2025.1520814.环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Macrophages are vital sentinels in innate immunity, and their functions cannot be performed without internal metabolic reprogramming. Mitochondrial dynamics, especially mitochondrial fusion and fission, contributes to the maintenance of mitochondrial homeostasis. The link between mitochondrial dynamics and macrophages in the past has focused on the immune function of macrophages. We innovatively summarize and propose a link between mitochondrial dynamics and macrophage metabolism. Among them, fusion-related FAM73b, MTCH2, SLP-2 (Stomatin-like protein 2), and mtSIRT, and fission-related Fis1 and MTP18 may be the link between mitochondrial dynamics and macrophage metabolism association. Furthermore, post-translational modifications (PTMs) of mtSIRT play prominent roles in mitochondrial dynamics-macrophage metabolism connection, such as deacetylates and hypersuccinylation. MicroRNAs such as miR-150, miR-15b, and miR-125b are also possible entry points. The metabolic reprogramming of macrophages through the regulation of mitochondrial dynamics helps improve their adaptability and resistance to adverse environments and provides therapeutic possibilities for various diseases.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40196123/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250408082135&v=2.18.0.post9+e462414">40196123</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11973336/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250408082135&v=2.18.0.post9+e462414">PMC11973336</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1520814>10.3389/fimmu.2025.1520814</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40196123</guid><pubDate> Tue, 08 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Pan Li</dc:creator><dc:creator> Zhengbo Fan</dc:creator><dc:creator> Yanlan Huang</dc:creator><dc:creator> Liang Luo</dc:creator><dc:creator> Xiaoyan Wu</dc:creator><dc:date> 2025-04-08</dc:date><dc:source>免疫学领域</dc:source><dc:title>Mitochondrial dynamics at the intersection of macrophage polarization and metabolism</dc:title><dc:identifier> pmid:40196123</dc:identifier><dc:identifier> pmc:PMC11973336</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1520814</dc:identifier></item><item><title> Pipelines for lymphocyte homeostasis maintenance during cancer immunotherapy</title><link/> https://pubmed.ncbi.nlm.nih.gov/40196122/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250408082135&amp;v=2.18.0.post9+e462414<description> In general, increasing lymphocyte entry into tumor microenvironment (TME) and limiting their efflux will have a positive effect on the efficacy of immunotherapy. Current studies suggest maintenance lymphocyte homeostasis during cancer immunotherapy through the two pipelines tumor-associated high endothelial venules and lymphatic vessels. Tumor-associated high endothelial venules (TA-HEVs) play a key role in cancer immunotherapy through facilitating lymphocyte trafficking to the tumor.尽管... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025 Mar 24;16:1522417. doi: 10.3389/fimmu.2025.1522417.环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> In general, increasing lymphocyte entry into tumor microenvironment (TME) and limiting their efflux will have a positive effect on the efficacy of immunotherapy. Current studies suggest maintenance lymphocyte homeostasis during cancer immunotherapy through the two pipelines tumor-associated high endothelial venules and lymphatic vessels. Tumor-associated high endothelial venules (TA-HEVs) play a key role in cancer immunotherapy through facilitating lymphocyte trafficking to the tumor. While tumor-associated lymphatic vessels, in contrast, may promote the egress of lymphocytes and restrict their function. Therefore, the two traffic control points might be potential to maintain lymphocyte homeostasis in cancer during immunotherapy. Herein, we highlight the unexpected roles of lymphocyte circulation regulated by the two gateways for through reviewing the biological characters and functions of TA-HEVs and tumor-associated lymphatic vessels in the entry, positioning and exit of lymphocyte cells in TME during anti-tumor immunity.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40196122/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250408082135&v=2.18.0.post9+e462414">40196122</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11973195/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250408082135&v=2.18.0.post9+e462414">PMC11973195</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1522417>10.3389/fimmu.2025.1522417</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40196122</guid><pubDate> Tue, 08 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Bensu Du</dc:creator><dc:creator> Jin Geng</dc:creator><dc:creator> Bin Wu</dc:creator><dc:creator> Houru Wang</dc:creator><dc:creator> Ru Luo</dc:creator><dc:creator> Hanmeng Liu</dc:creator><dc:creator> Rui Zhang</dc:creator><dc:creator> Fengping Shan</dc:creator><dc:creator> Lei Liu</dc:creator><dc:creator> Shuling Zhang</dc:creator><dc:date> 2025-04-08</dc:date><dc:source>免疫学领域</dc:source><dc:title>Pipelines for lymphocyte homeostasis maintenance during cancer immunotherapy</dc:title><dc:identifier> pmid:40196122</dc:identifier><dc:identifier> pmc:PMC11973195</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1522417</dc:identifier></item><item><title> Serum miRNA-186-3P and miRNA-382-3P constitute a novel Diagnostic miRNA signature for palindromic rheumatism</title><link/> https://pubmed.ncbi.nlm.nih.gov/40196121/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250408082135&amp;v=2.18.0.post9+e462414<description> CONCLUSION: A miRNA signature comprising miRNA-186-3p and miRNA-382-3p can effectively diagnose and differentiate PR from RA. This study provides a basis for the creation of a clinical miRNA signature for the diagnosis of PR. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025 Mar 24;16:1569846. doi: 10.3389/fimmu.2025.1569846.环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Palindromic rheumatism (PR) is a unique disease characterized by the intermittent inflammation of different joints that may progress to a variety of immune-related diseases. Unclear diagnostic criteria have limited the research on its pathogenesis and treatment options. Recently, microRNAs (miRNAs) have been used in the diagnosis of various diseases; however, the role of miRNAs in PR diagnosis remains unexplored. Using next-generation high-throughput sequencing (NGS), this study aimed to screen miRNAs specifically expressed in the serum of patients with PR to construct a miRNA signature and verify its diagnostic efficacy. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Patients with PR (N=4), patients with rheumatoid arthritis (RA; N=3), and healthy individuals (Con; N=3) were included in an exploration cohort. Differentially expressed miRNAs were screened using NGS to construct a miRNA signature, and bioinformatics tools were used to perform target gene enrichment analysis of the top 25 differentially expressed miRNAs, both upregulated and downregulated. RT-qPCR was used to verify the differential expression of the miRNA signature in three validation cohorts of patients with PR (N=27) and RA (N=30), and healthy individuals (N=31). The efficiency of the miRNA signature was evaluated using receiver operator characteristic (ROC) curves, an analytical method that assesses diagnostic accuracy. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: A total of 130 miRNAs were differentially expressed in the PR exploration cohort, including 35 upregulated and 95 downregulated compared to levels in the RA and healthy cohorts. miRNA-186-3p showed the largest upregulated difference and miRNA-382-3p the largest downregulated difference; these were selected to construct the miRNA signature. In the ROC curve of the validation cohort, the PR miRNA signature produced an area under the ROC curve (AUC) of 0.980 (95% CI 0.942-1.000) when distinguishing from healthy individuals and of 0.906 (95% CI 0.830-0.983) when distinguishing from RA patients. However, miRNA-186-3p and miRNA-382-3p levels were not associated with disease activity in patients with PR. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSION: A miRNA signature comprising miRNA-186-3p and miRNA-382-3p can effectively diagnose and differentiate PR from RA. This study provides a basis for the creation of a clinical miRNA signature for the diagnosis of PR.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40196121/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250408082135&v=2.18.0.post9+e462414">40196121</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11973322/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250408082135&v=2.18.0.post9+e462414">PMC11973322</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1569846>10.3389/fimmu.2025.1569846</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40196121</guid><pubDate> Tue, 08 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Fangfang Yuan</dc:creator><dc:creator> Zefu Weng</dc:creator><dc:creator> Qiong Yang</dc:creator><dc:creator> Jing Luo</dc:creator><dc:creator> Lina Ying</dc:creator><dc:creator> Haiyan Huang</dc:creator><dc:creator> Xin Zhang</dc:creator><dc:creator> Yahui Chen</dc:creator><dc:creator> Jixia Lin</dc:creator><dc:creator> Junhong He</dc:creator><dc:date> 2025-04-08</dc:date><dc:source>免疫学领域</dc:source><dc:title>Serum miRNA-186-3P and miRNA-382-3P constitute a novel Diagnostic miRNA signature for palindromic rheumatism</dc:title><dc:identifier> pmid:40196121</dc:identifier><dc:identifier> pmc:PMC11973322</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1569846</dc:identifier></item><item><title> Cytokine interactions and chemokine dysregulations in mastitis immunopathogenesis: insights from transcriptomic profiling of milk somatic cells in tropical Sahiwal (&lt;em>;Bos indicus&lt;/em>;) cows</title><link/> https://pubmed.ncbi.nlm.nih.gov/40196120/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250408082135&amp;v=2.18.0.post9+e462414<description> INTRODUCTION: Bovine mastitis causes a significant loss to the dairy industry by affecting the quantity and quality of milk. Addressing this challenge, the present study will leverage advanced omics techniques for early mastitis detection in early lactating Sahiwal cows (Bos indicus). This was the first differential transcriptomic study investigating the alterations in gene expression in milk somatic cells during the progression of naturally occurring mastitis in indigenous Sahiwal cows. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025 Mar 24;16:1554341. doi: 10.3389/fimmu.2025.1554341.环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> INTRODUCTION: Bovine mastitis causes a significant loss to the dairy industry by affecting the quantity and quality of milk. Addressing this challenge, the present study will leverage advanced omics techniques for early mastitis detection in early lactating Sahiwal cows ( <i>Bos indicus</i> ). This was the first differential transcriptomic study investigating the alterations in gene expression in milk somatic cells during the progression of naturally occurring mastitis in indigenous Sahiwal cows. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Cows were grouped into healthy (H), subclinical mastitis (SCM) and clinical mastitis (CM) groups by thoroughly screening them using the California Mastitis Test (CMT) and milk somatic cell counts (SCC). This was followed by detailed milk composition analysis, differential leukocyte counts (DLC), and microbiological culture. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: The differential gene expression of milk SCs through transcriptome profiling identified 83 and 76, up-regulated and 157 and 192 down-regulated genes in CM vs H and SCM vs H groups (log2 fold change ≥1 and ≤-1, p &lt; 0.05) respectively. Pathway analysis revealed that upregulated genes were enriched in pathways such as phagosome activity, IL-17 signalling, Th1 and Th2 cell differentiation, while downregulated genes were linked to RIG-I-like receptor signalling, NK cell cytotoxicity, and Toll-like receptor signalling and Cytokine-cytokine receptor interactions. Notably, the study underscores the roles of chemokines CCL8, CCL2, and CXCL10 in immune cell recruitment during mastitis, where their downregulation suggests impaired mammary immune defense that governs Chemokine signalling pathways. Further, the comparative analysis with the previously available milk SCs proteome data identified the downregulation of chemokines signalling pathways during mastitis. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> DISCUSSION: Overall, this research enhances our understanding of mastitis pathogenesis and emphasizes that these targeted chemokines may boost mammary resilience through immunomodulation, genetic selection and genome editing or by utilising adjuvants in vaccine development that restore chemokine signalling offers a potential strategy to improve mastitis resistance in dairy cattle.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40196120/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250408082135&v=2.18.0.post9+e462414">40196120</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11973270/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250408082135&v=2.18.0.post9+e462414">PMC11973270</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1554341>10.3389/fimmu.2025.1554341</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40196120</guid><pubDate> Tue, 08 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Lija Satheesan</dc:creator><dc:creator> Ajay Kumar Dang</dc:creator><dc:creator> Rani Alex</dc:creator><dc:date> 2025-04-08</dc:date><dc:source>免疫学领域</dc:source><dc:title>Cytokine interactions and chemokine dysregulations in mastitis immunopathogenesis: insights from transcriptomic profiling of milk somatic cells in tropical Sahiwal (&lt;em>;Bos indicus&lt;/em>;) cows</dc:title><dc:identifier> pmid:40196120</dc:identifier><dc:identifier> pmc:PMC11973270</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1554341</dc:identifier></item><item><title> Telitacicept as an alternative to non-steroidal immunosuppressive therapies in the treatment of myasthenia gravis: a study on clinical efficacy and steroid-sparing effect</title><link/> https://pubmed.ncbi.nlm.nih.gov/40196119/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250408082135&amp;v=2.18.0.post9+e462414<description> CONCLUSION: Telitacicept is effective in inducing MSE rapidly and offers a steroid-sparing effect, making it a promising alternative to traditional NSISTs with fewer side effects in MG patients. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025 Mar 24;16:1549034. doi: 10.3389/fimmu.2025.1549034.环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> INTRODUCTION: Myasthenia Gravis (MG) is an autoimmune disorder characterized by impaired neuromuscular junction (NMJ) transmission. Current treatments for MG include steroids and nonsteroidal immunosuppressive therapies (NSISTs). However, approximately 20% of patients show a poor response to these therapies, which are often associated with significant side effects. Telitacicept, a novel recombinant fusion protein targeting the BAFF/APRIL pathway, has shown promise in treating autoimmune diseases, including MG. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: This retrospective study compared the efficacy of telitacicept monotherapy (10 patients) to NSISTs (16 patients) and sequential therapy (6 patients) in managing Myasthenia Gravis (MG) at The First Affiliated Hospital of Wenzhou Medical University (July 2020-November 2024). The primary endpoint was the time to achieve minimal symptom expression (MSE), and secondary endpoint was the change in the mean daily prednisone dosage from baseline to month 4. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Among telitacicept-treated patients, 80% achieved MSE within 4 months, with a significant reduction in mean daily dose of prednisone (from 45.00 mg to 6.25 mg, <i>P</i> &lt; 0.001). In contrast, only 12.5% of the NSISTs group achieved MSE, with no significant change in mean daily dose of prednisone ( <i>P</i> = 0.091). The sequential therapy group (efgartigimod followed by telitacicept) maintained stable disease conditions. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSION: Telitacicept is effective in inducing MSE rapidly and offers a steroid-sparing effect, making it a promising alternative to traditional NSISTs with fewer side effects in MG patients.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40196119/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250408082135&v=2.18.0.post9+e462414">40196119</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11973063/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250408082135&v=2.18.0.post9+e462414">PMC11973063</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1549034>10.3389/fimmu.2025.1549034</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40196119</guid><pubDate> Tue, 08 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Zheyu Fang</dc:creator><dc:creator> Yuan Zhang</dc:creator><dc:creator> Yu Zhang</dc:creator><dc:creator> Qiaoyi Zhang</dc:creator><dc:creator> Xi Qu</dc:creator><dc:creator> Shengli Pan</dc:creator><dc:creator> Bingbing Wan</dc:creator><dc:creator> Shiyin Yang</dc:creator><dc:creator> Xu Zhang</dc:creator><dc:creator> Jia Li</dc:creator><dc:date> 2025-04-08</dc:date><dc:source>免疫学领域</dc:source><dc:title>Telitacicept as an alternative to non-steroidal immunosuppressive therapies in the treatment of myasthenia gravis: a study on clinical efficacy and steroid-sparing effect</dc:title><dc:identifier> pmid:40196119</dc:identifier><dc:identifier> pmc:PMC11973063</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1549034</dc:identifier></item></channel></rss>